Surrogate end points in cardiovascular disease trials

American Heart Journal

Volumn 139, Issue 4, 2000, Pages

  Fleming, Thomas R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL RESEARCH; CONFERENCE PAPER; DISEASE MARKER; DOSE RESPONSE; HEART ARRHYTHMIA; HEART FUNCTION; HUMAN; MORBIDITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0034126842     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90071-1     Document Type: Conference Paper

References (14)

1. 1. Temple RJ. A regulatory authority's opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, editors. Clinical measurement in drug evaluation. New York: John Wiley; 1995; p. 322.
2. 2. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
3. 3. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
4. 4. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993;88[suppl 1]: 1-301.
5. 5. Bode C, Smolling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction; the RAPID II Investigators. Circulation 1996;94:891-8.
6. 6. Gordon DJ. Cholesterol lowering and total mortality. In: Rifkind BM, editor. Contemporary issues in cholesterol lowering: clinical and population aspects. New York: Marcel Dekker; 1994.
7. 7. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
8. 8. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
9. 9. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
10. 10. DeGruttola V, Fleming T, Lin DY, et al. Validating surrogate markers: are we being naive? J Infect Dis 1997; 175:237-46.
11. 11. Lin DY, Fleming TR, DeGruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997; 16:1515-27.
12. 12. SHEP Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:2355-3264.
13. 13. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299:1187-92.
14. 14. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiobgic context. Lancet 1990;335:827-38. Am Heart J 2000;139:S200-S201.